AstraZeneca's Crestor patent upheld in US
This article was originally published in Scrip
Executive Summary
AstraZeneca's shares rose by 9% to open at £32.03 on the London Stock Exchange on 30 June after a US district court upheld its patent for the cholesterol therapy Crestor (rosuvastatin).